ASA404 fails second late-stage lung cancer trial

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 19 No 12
Volume 19
Issue 12

Novartis and its partner Antisoma announced that an interim analysis of data from a late-stage trial showed that vadimezam (ASA404) was unlikely to provide any benefit as a second-line treatment for patients with non-small-cell lung cancer. As a result, Novartis indicated that it would halt development of the compound, which was designed to inhibit angiogenesis.

Novartis and its partner Antisoma announced that an interim analysis of data from a late-stage trial showed that vadimezam (ASA404) was unlikely to provide any benefit as a second-line treatment for patients with non-small-cell lung cancer. As a result, Novartis indicated that it would halt development of the compound, which was designed to inhibit angiogenesis.

The ATTRACT-2 study enrolled patients with advanced NSCLC whose disease had progressed after first-line therapy. In ATTRACT-1, ASA404 failed to demonstrate a survival benefit in previously untreated patients with NSCLC when used in combination with chemotherapy.

Articles in this issue
Roche Gains OK in Europe for Rituximab for Maintenance
JAK inhibitor quells symptoms linked to myelofibrosis
E-Charts help track course of febrile events in hematology
E-Charts help track course of febrile events in hematology
Colon Cancer Patients With p.G13D KRAS Mutations See Better Survival With Cetuximab-Based Therapy
Colon Cancer Patients With p.G13D KRAS Mutations See Better Survival With Cetuximab-Based Therapy
Duke Cancer Center Lands Renewal of $30 Million Grant
Even Insured Cancer Patients May Stumble Over Co-pays and Drug Costs
Even Insured Cancer Patients May Stumble Over Co-pays and Drug Costs
New Jersey cancer center features green lobby
New Jersey cancer center features green lobby
Long Constitutional Telomere Length May Serve as Measure for Colon Cancer Risk in Younger Patients
Long Constitutional Telomere Length May Serve as Measure for Colon Cancer Risk in Younger Patients
Short Course of Radiation Therapy Before Total Mesorectal Excision Lowers Local Recurrence Rate
Short Course of Radiation Therapy Before Total Mesorectal Excision Lowers Local Recurrence Rate
Growing number of pts undergo radiotherapy
Low-intensity electric-field Rx boosts chemo in NSCLC
Melanoma: Rose Bengal Scores, Ipilimumab Sees Delay
Melanoma: Rose Bengal Scores, Ipilimumab Sees Delay
Postgastrectomy Patients May Benefit From HP Eradication Rx
Postgastrectomy Patients May Benefit From HP Eradication Rx
Post-lumpectomy RT lowers risk of recurrence
Post-lumpectomy RT lowers risk of recurrence
CMS: Provenge shows evidence of ‘moderate’ benefit
CMS: Provenge shows evidence of ‘moderate’ benefit

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
The FirstLook liquid biopsy, when used as an adjunct to low-dose CT, may help to address the unmet need of low lung cancer screening utilization.
An 80% sensitivity for lung cancer was observed with the liquid biopsy, with high sensitivity observed for early-stage disease, as well.
Patients who face smoking stigma, perceive a lack of insurance, or have other low-dose CT related concerns may benefit from blood testing for lung cancer.
Video 4 - "Frontline Treatment for EGFR-Mutated Lung Cancer"
Related Content
A futility analysis showed that ociperlimab was unlikely to reach the primary end point of overall survival as part of the phase 3 AdvanTIG-302 trial.

Developers Terminate Clinical Program for Ociperlimab in Lung Cancer

Russ Conroy
April 3rd 2025
Article

A futility analysis showed that ociperlimab was unlikely to reach the primary end point of overall survival as part of the phase 3 AdvanTIG-302 trial.

Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.

Exploring the Value of Preoperative CAPTEM in Atypical Lung NETs

Georgios Evangelou, MD, MSc
September 16th 2024
Podcast

Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.

A stronger commitment to tobacco control at the local, state, and federal levels may further improve progress in preventing smoking-related mortality.

Tobacco Control Helps Avert Millions of Lung Cancer Deaths

Russ Conroy
March 27th 2025
Article

A stronger commitment to tobacco control at the local, state, and federal levels may further improve progress in preventing smoking-related mortality.

Rian M. Hasson Charles, MD, MPH, FACS, discusses advances in equitable lung cancer screening and her experiences as a woman in thoracic oncology.

Achieving Health Equity in Lung Cancer Surgery

Rian M. Hasson Charles, MD, MPH, FACS
April 1st 2024
Podcast

Rian M. Hasson Charles, MD, MPH, FACS, discusses advances in equitable lung cancer screening and her experiences as a woman in thoracic oncology.

AI/ML-Based Software Improves Diagnostic Accuracy in Lung Cancer

AI/ML-Based Software Improves Diagnostic Accuracy in Lung Cancer

Tim Cortese
February 5th 2025
Article

The diagnostic accuracy of radiologists aided by the eyonis LCS AI software was greatly improved compared with when radiologists were unaided.

Lung cancer

Deep Learning Models Expedite Biomarker Discovery, Detection in Lung Cancer

Silas Inman
September 7th 2024
Article

Investigators showcased feasibility of combining pathology findings with deep learning artificial intelligence to speed up biomarker detection and discovery for patients with lung cancer.